RZLT
Rezolute, Inc. Common Stock (NV)#11 · 2024BreakoutBYearly return
+383%
Peak return
+509%
Max drawdown
-40%
ADR (20 days)
+7.4%
Base
13 days / -47.5%
Prior run
+414%
Breakout volume
1.6x
Pivot
$4.73
Catalyst FDA/Clinical2024-05-21Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)GlobeNewswire Inc.
Biotech-/Medtech-News mit binaerem Daten-, Zulassungs- oder Studiencharakter.
Healthcare · Healthcare & Biotech
Continue in the full Atlas
Drawing, alerts, replay and the live scanner built on the same criteria are part of WickedDesk. Compare RZLT with the current market directly.